Research ExplorerPublicationsDeterminants of patient and physician global assessments of ...

Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis

Standard

Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. / Rohde, Marius; Kernder, Anna; Acar, Hasan; Düsing, Christina; Fischer-Betz, Rebecca; Haase, Isabell; Mucke, Johanna; Sander, Oliver; Richter, Jutta; Filla, Tim; Schneider, Matthias; Chehab, Gamal.

In: FRONT MED-LAUSANNE, Vol. 10, 2023, p. 1107148.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Rohde, M, Kernder, A, Acar, H, Düsing, C, Fischer-Betz, R, Haase, I, Mucke, J, Sander, O, Richter, J, Filla, T, Schneider, M & Chehab, G 2023, 'Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis', FRONT MED-LAUSANNE, vol. 10, pp. 1107148. https://doi.org/10.3389/fmed.2023.1107148

APA

Rohde, M., Kernder, A., Acar, H., Düsing, C., Fischer-Betz, R., Haase, I., Mucke, J., Sander, O., Richter, J., Filla, T., Schneider, M., & Chehab, G. (2023). Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. FRONT MED-LAUSANNE, 10, 1107148. https://doi.org/10.3389/fmed.2023.1107148

Vancouver

Rohde M, Kernder A, Acar H, Düsing C, Fischer-Betz R, Haase I et al. Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. FRONT MED-LAUSANNE. 2023;10:1107148. https://doi.org/10.3389/fmed.2023.1107148

Bibtex

@article{6c4816ca79c2460e95c747c563f1f9f9,
title = "Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis",
abstract = "OBJECTIVE: To compare physician and patient assessments of global disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and to identify associated factors.METHODS: Global disease activity scores (0-10 points) were retrospectively analyzed from physicians and patients with AAV at each outpatient visit from 2010 to 2020. We compared the scores and performed a linear regression with a random effects to identify associated factors.RESULTS: Patients (n = 143, 1,291 pairs, 52% female) had a mean 64 (±15) years of age and a mean disease duration of 9 (±7) years. Patients and physicians global disease activity assessments showed a moderate correlation (Pearson R 0.31, CI [0.23-0.52], p < 0.001). Linear regression showed a strong association between the physician-documented disease activity scores and serum CRP levels (β = 0.22, CI [0.18, 0.28]), disease duration (β = -0.022, CI [-0.04,-0.01]) and patients' assessment of disease activity (β = 0.08, CI [0.04, 0.12]). By contrast, patient assessments were strongly associated with the degree of pain (β = 0.30, CI [0.25, 0.35]), functional limitations in daily living (HAQ, β = 0.49, CI [0.21, 0.78]) and the global physical well-being (NRS, β = 0.39, CI [0.32, 0.46]).CONCLUSION: Patients' and physicians' assessments of disease activity correlated. High CRP levels and disease duration were associated with physician-assessed disease activity scores, while subjective limitations were associated with higher patient-assessed disease activity scores. These findings highlight and support the need to develop and evaluate patient-reported outcomes to assess disease activity in patients diagnosed with AAV.",
author = "Marius Rohde and Anna Kernder and Hasan Acar and Christina D{\"u}sing and Rebecca Fischer-Betz and Isabell Haase and Johanna Mucke and Oliver Sander and Jutta Richter and Tim Filla and Matthias Schneider and Gamal Chehab",
note = "Copyright {\textcopyright} 2023 Rohde, Kernder, Acar, D{\"u}sing, Fischer-Betz, Haase, Mucke, Sander, Richter, Filla, Schneider and Chehab.",
year = "2023",
doi = "10.3389/fmed.2023.1107148",
language = "English",
volume = "10",
pages = "1107148",
journal = "FRONT MED-LAUSANNE",
issn = "2296-858X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Determinants of patient and physician global assessments of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis

AU - Rohde, Marius

AU - Kernder, Anna

AU - Acar, Hasan

AU - Düsing, Christina

AU - Fischer-Betz, Rebecca

AU - Haase, Isabell

AU - Mucke, Johanna

AU - Sander, Oliver

AU - Richter, Jutta

AU - Filla, Tim

AU - Schneider, Matthias

AU - Chehab, Gamal

N1 - Copyright © 2023 Rohde, Kernder, Acar, Düsing, Fischer-Betz, Haase, Mucke, Sander, Richter, Filla, Schneider and Chehab.

PY - 2023

Y1 - 2023

N2 - OBJECTIVE: To compare physician and patient assessments of global disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and to identify associated factors.METHODS: Global disease activity scores (0-10 points) were retrospectively analyzed from physicians and patients with AAV at each outpatient visit from 2010 to 2020. We compared the scores and performed a linear regression with a random effects to identify associated factors.RESULTS: Patients (n = 143, 1,291 pairs, 52% female) had a mean 64 (±15) years of age and a mean disease duration of 9 (±7) years. Patients and physicians global disease activity assessments showed a moderate correlation (Pearson R 0.31, CI [0.23-0.52], p < 0.001). Linear regression showed a strong association between the physician-documented disease activity scores and serum CRP levels (β = 0.22, CI [0.18, 0.28]), disease duration (β = -0.022, CI [-0.04,-0.01]) and patients' assessment of disease activity (β = 0.08, CI [0.04, 0.12]). By contrast, patient assessments were strongly associated with the degree of pain (β = 0.30, CI [0.25, 0.35]), functional limitations in daily living (HAQ, β = 0.49, CI [0.21, 0.78]) and the global physical well-being (NRS, β = 0.39, CI [0.32, 0.46]).CONCLUSION: Patients' and physicians' assessments of disease activity correlated. High CRP levels and disease duration were associated with physician-assessed disease activity scores, while subjective limitations were associated with higher patient-assessed disease activity scores. These findings highlight and support the need to develop and evaluate patient-reported outcomes to assess disease activity in patients diagnosed with AAV.

AB - OBJECTIVE: To compare physician and patient assessments of global disease activity in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and to identify associated factors.METHODS: Global disease activity scores (0-10 points) were retrospectively analyzed from physicians and patients with AAV at each outpatient visit from 2010 to 2020. We compared the scores and performed a linear regression with a random effects to identify associated factors.RESULTS: Patients (n = 143, 1,291 pairs, 52% female) had a mean 64 (±15) years of age and a mean disease duration of 9 (±7) years. Patients and physicians global disease activity assessments showed a moderate correlation (Pearson R 0.31, CI [0.23-0.52], p < 0.001). Linear regression showed a strong association between the physician-documented disease activity scores and serum CRP levels (β = 0.22, CI [0.18, 0.28]), disease duration (β = -0.022, CI [-0.04,-0.01]) and patients' assessment of disease activity (β = 0.08, CI [0.04, 0.12]). By contrast, patient assessments were strongly associated with the degree of pain (β = 0.30, CI [0.25, 0.35]), functional limitations in daily living (HAQ, β = 0.49, CI [0.21, 0.78]) and the global physical well-being (NRS, β = 0.39, CI [0.32, 0.46]).CONCLUSION: Patients' and physicians' assessments of disease activity correlated. High CRP levels and disease duration were associated with physician-assessed disease activity scores, while subjective limitations were associated with higher patient-assessed disease activity scores. These findings highlight and support the need to develop and evaluate patient-reported outcomes to assess disease activity in patients diagnosed with AAV.

U2 - 10.3389/fmed.2023.1107148

DO - 10.3389/fmed.2023.1107148

M3 - SCORING: Journal article

C2 - 36844213

VL - 10

SP - 1107148

JO - FRONT MED-LAUSANNE

JF - FRONT MED-LAUSANNE

SN - 2296-858X

ER -